Biomaterial Database

[Inotropic agents in the treatment of congestive heart failure]. 1993

M Iizuka

1st Department of Internal Medicine, Dokkyo University School of Medicine.

UI	MeSH Term	Description	Entries
D011728	Pyridones	Pyridine derivatives with one or more keto groups on the ring.	Pyridinones
D002316	Cardiotonic Agents	Agents that have a strengthening effect on the heart or that can increase cardiac output. They may be CARDIAC GLYCOSIDES; SYMPATHOMIMETICS; or other drugs. They are used after MYOCARDIAL INFARCT; CARDIAC SURGICAL PROCEDURES; in SHOCK; or in congestive heart failure (HEART FAILURE).	Cardiac Stimulant,Cardiac Stimulants,Cardioprotective Agent,Cardioprotective Agents,Cardiotonic,Cardiotonic Agent,Cardiotonic Drug,Inotropic Agents, Positive Cardiac,Myocardial Stimulant,Myocardial Stimulants,Cardiotonic Drugs,Cardiotonics,Agent, Cardioprotective,Agent, Cardiotonic,Drug, Cardiotonic,Stimulant, Cardiac,Stimulant, Myocardial
D006333	Heart Failure	A heterogeneous condition in which the heart is unable to pump out sufficient blood to meet the metabolic need of the body. Heart failure can be caused by structural defects, functional abnormalities (VENTRICULAR DYSFUNCTION), or a sudden overload beyond its capacity. Chronic heart failure is more common than acute heart failure which results from sudden insult to cardiac function, such as MYOCARDIAL INFARCTION.	Cardiac Failure,Heart Decompensation,Congestive Heart Failure,Heart Failure, Congestive,Heart Failure, Left-Sided,Heart Failure, Right-Sided,Left-Sided Heart Failure,Myocardial Failure,Right-Sided Heart Failure,Decompensation, Heart,Heart Failure, Left Sided,Heart Failure, Right Sided,Left Sided Heart Failure,Right Sided Heart Failure
D006801	Humans	Members of the species Homo sapiens.	Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D015996	Survival Rate	The proportion of survivors in a group, e.g., of patients, studied and followed over a period, or the proportion of persons in a specified group alive at the beginning of a time interval who survive to the end of the interval. It is often studied using life table methods.	Cumulative Survival Rate,Mean Survival Time,Cumulative Survival Rates,Mean Survival Times,Rate, Cumulative Survival,Rate, Survival,Rates, Cumulative Survival,Rates, Survival,Survival Rate, Cumulative,Survival Rates,Survival Rates, Cumulative,Survival Time, Mean,Survival Times, Mean,Time, Mean Survival,Times, Mean Survival
D020105	Milrinone	A positive inotropic cardiotonic agent with vasodilator properties. It inhibits cAMP phosphodiesterase type 3 activity in myocardium and vascular smooth muscle. Milrinone is a derivative of amrinone and has 20-30 times the inotropic potency of amrinone.	Corotrop,Corotrope,Milrinone Lactate,Primacor,Win-47203,Lactate, Milrinone,Win 47203,Win47203

Related Publications

M Iizuka

[New inotropic agents in the treatment of congestive heart failure].

January 1982, Terapevticheskii arkhiv,

M Iizuka

[New inotropic agents in the treatment of congestive heart failure].

November 1993, Revista portuguesa de cardiologia : orgao oficial da Sociedade Portuguesa de Cardiologia = Portuguese journal of cardiology : an official journal of the Portuguese Society of Cardiology,

M Iizuka

[Positive inotropic agents in the treatment of congestive heart failure].

March 1987, Kokyu to junkan. Respiration & circulation,

M Iizuka

Positive inotropic agents in congestive heart failure.

January 1993, Coronary artery disease,

M Iizuka

Vasodilators and inotropic agents in the treatment of congestive heart failure.

September 1994, Seminars in nephrology,

M Iizuka

[New inotropic agents in the treatment of refractory congestive heart failure].

March 1988, Harefuah,